KRW 96700.0
(-6.84%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 41.28 Billion KRW | 25.35% |
2022 | 32.93 Billion KRW | -4.43% |
2021 | 34.45 Billion KRW | 44.87% |
2020 | 23.78 Billion KRW | -6.97% |
2019 | 25.56 Billion KRW | 55.98% |
2018 | 16.39 Billion KRW | -49.99% |
2017 | 32.77 Billion KRW | 11.13% |
2016 | 29.49 Billion KRW | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 114.34 Billion KRW | -16.75% |
2024 Q1 | 137.35 Billion KRW | 232.74% |
2023 Q1 | 34.44 Billion KRW | 4.6% |
2023 Q4 | 41.28 Billion KRW | 10.66% |
2023 Q3 | 37.3 Billion KRW | 15.98% |
2023 Q2 | 32.16 Billion KRW | -6.62% |
2023 FY | 41.28 Billion KRW | 25.35% |
2022 Q3 | 31.5 Billion KRW | -10.54% |
2022 Q4 | 32.93 Billion KRW | 4.54% |
2022 Q2 | 35.21 Billion KRW | -0.84% |
2022 Q1 | 35.5 Billion KRW | 3.05% |
2021 Q3 | 29.95 Billion KRW | 0.0% |
2021 Q4 | 34.45 Billion KRW | 15.03% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
HLB Co., Ltd. | 169.47 Billion KRW | 75.642% |
iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -2095.37% |
BINEX Co., Ltd. | 75.68 Billion KRW | 45.458% |
Bioneer Corporation | 80.61 Billion KRW | 48.79% |
Anterogen.Co.,Ltd. | 19.98 Billion KRW | -106.541% |
MEDIPOST Co., Ltd. | 135.73 Billion KRW | 69.587% |
CrystalGenomics, Inc. | 97.82 Billion USD | 57.8% |
Helixmith Co., Ltd | 73.55 Billion KRW | 43.879% |
Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 96.139% |
Medy-Tox Inc. | 137.14 Billion KRW | 69.899% |
Peptron, Inc. | 16.36 Billion KRW | -152.19% |
Amicogen, Inc. | 248.12 Billion KRW | 83.363% |
Genexine, Inc. | 79.68 Billion KRW | 48.194% |
HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | -41.006% |
ALTEOGEN Inc. | 108.25 Billion KRW | 61.868% |
PharmaResearch Co., Ltd. | 73.08 Billion KRW | 43.518% |
SillaJen, Inc. | 19.4 Billion KRW | -112.778% |
JETEMA, Co., Ltd. | 179.09 Billion KRW | 76.95% |
OliX Pharmaceuticals,Inc | 52.48 Billion KRW | 21.353% |
Genomictree Inc. | 7.81 Billion KRW | -428.412% |
MedPacto, Inc. | 9.56 Billion KRW | -331.55% |
D&D Pharmatech | 23.98 Billion KRW | -72.107% |
EASY BIO,Inc. | 105.86 Billion KRW | 61.007% |
GI Innovation, Inc. | 9.63 Billion KRW | -328.394% |